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Abstract
The transcription factor RUNX1, a pivotal regulator of HSCs and haematopoiesis, is 
a frequent target of chromosomal translocations, point mutations or altered gene/
protein dosage. These modifications lead or contribute to the development of my-
elodysplasia, leukaemia or platelet disorders. A better understanding of how regu-
latory elements contribute to fine-tune the RUNX1 expression in haematopoietic 
tissues could improve our knowledge of the mechanisms responsible for normal 
haematopoiesis and malignancy insurgence. The cohesin RAD21 was reported to 
be a regulator of RUNX1 expression in the human myeloid HL60 cell line and dur-
ing primitive haematopoiesis in zebrafish. In our study, we demonstrate that another 
cohesin, NIPBL, exerts positive regulation of RUNX1 in three different contexts in 
which RUNX1 displays important functions: in megakaryocytes derived from healthy 
donors, in bone marrow samples obtained from adult patients with acute myeloid 
leukaemia and during zebrafish haematopoiesis. In this model, we demonstrate that 
alterations in the zebrafish orthologue nipblb reduce runx1 expression with conse-
quent defects in its erythroid and myeloid targets such as gata1a and spi1b in an op-
posite way to rad21. Thus, also in the absence of RUNX1 translocation or mutations, 
additional factors such as defects in the expression of NIPBL might induce haemato-
logical diseases.
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1  | INTRODUC TION
In all vertebrates, the RUNX family of transcriptional regula-
tors containing the runt domain (RD) comprises three isoforms: 
RUNX1, RUNX2 and RUNX3 that, together with the non-DNA-
binding CBFβ subunit, regulate many developmental processes.1,2 
The RUNX members specify their functions depending on their 
cellular and tissue expression: RUNX1 plays a key role in blood 
development, primarily in the haematopoietic stem cells (HSCs), 
RUNX2 is manly involved in bone morphogenesis, and RUNX3 in 
cell growth of neurons, epithelial cells and T cells. However, the 
three RUNX proteins could exert biological activities also in other 
organs3–5; for example, RUNX2 and RUNX3 are known to play a 
role during haematopoiesis together with RUNX1. In addition, 
all the RUNX genes are transcribed by a distal and a proximal pro-
moter (P1 and P2, respectively) in two main isoforms that differ 
in the 5′UTR and in the coding sequence of the first exon.6,7 The 
P1 and P2RUNX transcripts are differentially expressed in diverse 
cell types and during specific developmental stages. Indeed, P1 
and P2RUNX1 promoters have been reported to have specific 
activity patterns in the different haematopoietic lineages during 
development.8
RUNX1 function during haematopoiesis is strictly regulated 
by post-transcriptional and post-translational modifications such 
as alternative splicing, acetylation, methylation, phosphorylation 
and ubiquitination.9 As transcription factor, RUNX1 targets multi-
ple genes, many of which are also pivotal transcriptional regulators 
involved in the formation of all haematopoietic lineages including 
the haematopoietic-specific member of E-twenty-six (ETS) family, 
PU.1.10,11 Furthermore, the activity of RUNX1 is carried out by its 
interaction with different proteins fundamental during haematopoi-
esis such as GATA1, PU.1, CEBPA, PAX5 and ETS1.10,12–14
Given the high complexity in RUNX1 expression and function, 
its deregulation is commonly associated with haematopoietic dis-
eases. Depletion of Runx1 in mice and zebrafish models leads to 
severe defects or complete absence of definitive haematopoi-
esis.15–18 RUNX1 is frequently involved in chromosomal translo-
cations observed in acute leukaemias, such as ETV6-RUNX1 in 
t(12;21) and RUNX1-EVI1 in t(3;21),19 while the formation of the 
chimeric protein RUNX1-CBF2T1 (AML1-ETO) is associated with 
the M2 subtype of acute myeloid leukaemia (AML).20,21 RUNX1 
mutations determine the familial platelet disorder with a propen-
sity for AML (AML/FPD) and the minimally differentiated acute 
myeloid leukaemia (AML/M0).22 Importantly, regulation of RUNX1 
dosage is essential for the maintenance of normal haematopoie-
sis23 and several haematopoietic transcription factors are deputed 
to regulate RUNX1 expression such as Gata2, Ets factors (Fli-1, 
Elf-1 and Pu.1) and the SCL/Lmo2/Ldb1 complex.24 In zebrafish, 
the subunit Rad21 of the cohesin complex has been identified 
as a regulator of runx1 through a forward genetic screen,25 and 
multiple predicted and in vivo validated binding sites of Rad21 
have been shown to be involved in the regulation of the zebrafish 
runx1.26
In this work, we demonstrate that NIPBL, another member of 
the cohesin complex, positively regulates RUNX1 expression in two 
different contexts in which it exerts important functions: normal 
cord blood megakaryocytes derived from healthy donors and bone 
marrow samples derived from adult AML patients. In addition, we 
generate a zebrafish model in which the nipblb-mediated dysregula-
tion of runx1 expression leads to haematopoietic defects resulting in 
decreased expression of the erythroid marker gata1a and reduction 
of mature circulating erythrocytes, and increased expression of my-
eloid precursors positive for the spi1b marker. Our data confirm the 
regulatory loop between RUNX1-GATA1 and PU.1 during haemato-
poiesis and highlight a new role of NIPBL on top of this route.
2  | MATERIAL S AND METHODS
2.1 | Patients
Diagnostic bone marrow samples from 34 adult patients affected 
by AML were collected and characterized for specific molecular 
aberrancies, including translocations t(9;22), t(8;21) and inv(16), in 
accordance with specific clinical protocol requirements. The ana-
lysed patients belong to different French-American-British (FAB) 
classification systems (FABs), excluding M3; therefore, all patients 
were negative for translocation t(15;17) (Table 1). Bone marrow of 
healthy individuals was collected as controls for gene expression 
assays, upon appropriate informed consent ASG-A-052A approved 
on 8 May 2012 by Azienda Socio-Sanitaria of Monza (ASST-Monza). 
Human material and derived data were used in accordance with the 
Declaration of Helsinki.
2.2 | Animals
Zebrafish embryos were raised and maintained according to in-
ternational (European Union Directive 2010/63/EU) and national 
(Italian decree no. 26 of 4 March 2014) guidelines on the protec-
tion of animals used for scientific purposes. The fish were main-
tained under standard conditions in the fish facilities of Bioscience 
Dept, University of Milan, Via Celoria 26-20133 Milan, Italy (Aut. 
Prot, n. 295/2012-A—20 December 2012). We express the embry-
onic ages in hours post-fertilization (hpf) and days post-fertilization 
(dpf). Zebrafish AB strains obtained from the Wilson laboratory 
(University College London, London, UK) and Tg(fli1a:EGFP)y1 27 were 
maintained at 28°C on a 14-h light/10-h dark cycle. Embryos were 
collected by natural spawning, staged according to Ref. 28 and raised 
at 28°C in fish water (Instant Ocean, 0,1% Methylene Blue) in Petri 
dishes, according to established techniques. To prevent pigmenta-
tion, 0,003% 1-phenyl-2-thiourea (PTU, Sigma-Aldrich) was added to 
the fish water prior to 24 hpf. Before observations and picture ac-
quisitions, embryos were washed, dechorionated and anaesthetized, 
with 0.016% tricaine (ethyl 3-aminobenzoate methanesulfonate salt; 
Sigma-Aldrich).
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2.3 | Reverse transcription and real-time 
quantitative polymerase chain reaction assays (RT-
qPCR)
RNA was extracted from human and zebrafish embryos using TRIzol 
reagents (Life Technologies), following the manufacturer's protocol. 
For human samples and RT-qPCR experiments, Superscript II enzyme 
(Life Technologies) was used for cDNA synthesis. For this set of ex-
periments, a LightCycler 480II (Roche Diagnostics, Basel, Swiss) was 
used. Probes were selected according to the Software Probe Finder 
(Roche Diagnostics) and are reported in Table 2. hGUS gene was used 
as reference gene in human patients and cells derived from healthy 
donors as standard control. For zebrafish samples, DNase I RNase-
free (Roche Diagnostics) treatment was performed to avoid possible 
TA B L E  1   Clinical Features of patients' cohort
Age at 
onset Karyotype FAB classification NPM FLT3-ITD t(9;22) t(8;21) inv(16)
1 47 46,XX,t(10;11)(p11;p15)[20] M0 NEG NEG NEG NEG NEG
2 49 46,XY[20] M0/M1 NEG NEG NEG NEG NEG
3 48 46,XX[20] M1 NEG NEG NEG NEG NEG
4 72 47,XY,+mar[10]/46,XY[10] M2 NEG NEG NEG NEG NEG
5 58 46,XX,t(3;5)(q25;q34)[20] M2 NEG NEG NEG NEG NEG
6 59 46,XY[20]  NEG POS NEG NEG NEG
7 33 46,XY[15] M1 NEG POS NEG NEG NEG
8 30 46,XY[20] M5 NEG POS nk NEG NEG
9 58 46,XY,inv(16)(p13q22)[20] M4 NEG POS nk NEG POS
10 76 nk M5 NEG POS nk NEG NEG
11 78 46,XX[27] M4 NEG POS nk NEG NEG
12 53 46,XY[22] M4 NEG POS nk NEG NEG
13 64 46,XX[20] M5 NEG POS nk NEG NEG
14 75 46,XY[26] M4 NEG POS nk NEG NEG
15 39 46,XY[20] M1 POS (A) NEG NEG NEG NEG
16 47 46,XX[20] M5 POS (A) NEG NEG NEG NEG
17 63 46,XY,t(8;14)(q24;q32),add(13q34)[18]/46,XY[9] nk POS (D) NEG nk NEG NEG
18 58 46,XY/47,XY,+8[7/10] nk POS (QM) NEG nk NEG NEG
19 50 46,XX[20] M4 POS (A) NEG nk NEG NEG
20 77 46,XY[20] nk POS (A) NEG nk NEG NEG
21 54 46,XX,t(9;22)(q34;q11)[14]/46,XX[6] M4 POS (A) NEG POS NEG NEG
22 60 46,XX[6] nk POS NEG nk NEG NEG
23 62 46,XX[25] M5 POS (A) NEG ITD/
POS 
D835/
D836
nk NEG NEG
24 58 46,XX[20] nk POS (A) NEG nk NEG NEG
25 48 46,XX[20] M4 POS (A) POS NEG NEG NEG
26 51 46,XX[20] M5 POS (A) POS NEG NEG NEG
27 68 46,XX[20] M4 POS (A) POS ITD/
POS 
D835/
D836
NEG NEG NEG
28 46 46,XY[20] M2 POS POS NEG NEG NEG
29 39 46,XX[22] M1 POS (A) POS nk NEG NEG
30 58 46,XY M5 POS (A) POS nk NEG NEG
31 35 46,XY,?r(18)(?)[16]/47,idem,+8[3]/46,XY[1] nk POS (B) POS nk NEG NEG
32 58 46,XY[24] M1 POS (A) POS nk NEG NEG
33 70 46,XY[20] M5 POS (A) POS nk NEG NEG
34 12 46,XY[24] nk POS (A) POS NEG NEG NEG
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genomic contamination and 1 μg of RNA was reverse-transcribed 
using the “ImProm-II™ Reverse Transcription System” (Promega). 
RT-qPCRs were carried out in a total volume of 20 μl containing 1X 
iQ SYBR Green Supermix (Promega), using proper amount of the RT 
reaction and a mixture of oligo(dT) and random primers according 
to manufacturer's instructions. RT-qPCRs were performed using the 
Bio-Rad iCycler iQ Real-Time Detection System (Bio-Rad). For nor-
malization purposes, rpl8 expression levels were tested in parallel 
with the gene of interest. Primers are reported in Table 3. Expression 
levels in the Y-axis were relative to the control.
2.4 | In situ hybridization, o-dianisidine and 
immunofluorescence analyses
Whole-mount in situ hybridization (WISH) experiments were car-
ried out as described by Thisse et al.29 For quantification of the 
observed phenotypes, WISH experiments were done at least in 
3 independent batches of embryos (minimum 15-20 embryos for 
each category). Embryos were fixed overnight in 4% paraformal-
dehyde (PFA, Sigma-Aldrich) in phosphate-buffered saline (PBS) 
at 4°C, and then dehydrated stepwise to methanol and stored 
at −20°C. Antisense riboprobes were previously in vitro labelled 
with modified nucleotides (i.e. digoxigenin, Roche Diagnostics). 
runx1,30 spi1b31 and gata1a32 probes were synthesized according 
to literature. To detect haemoglobin activity, o-dianisidine (Sigma) 
staining was performed as described in Ref. 33. Controls and MO-
injected embryos at the same developmental stage were scored 
from 1 to 3 according to the intensity of the staining by micros-
copy, and o-dianisidine-positive cells on the yolk surface and in the 
Caudal haematopoietic tissue (CHT) were compared.
2.5 | Injections
Injections were carried out on one- to two-cell stage embryos. 
Details of concentration and sequence of nipblb morpholino (nip-
blb-MO, Gene Tools, Oregon, US) and rad21-MO (Gene Tools) are 
described in Ref. 34 and Ref. 25, respectively. In all experiments, MO-
injected embryos were compared to embryos at the same develop-
mental stage injected with the same amount of a ctrl-MO that has 
no target in zebrafish (Gene Tools LLC). The runx1/PCS2+ construct 
was kindly provided by C.E. Burns18 and injected at a concentration 
of 200 pg/embryo.
2.6 | Statistical analyses
For RT-qPCR experiments, data were statistically analysed applying 
one-way analysis of variance (ANOVA), defining P ≤ .05 (*), P ≤ .01 
(**) and P ≤ .001 (***) as statistically significant values.35 Data were 
analysed using the comparative ΔΔCt method. Both ANOVA and 
PRIMER length sequence PROBE
hGUS-L 20 CGCCCTGCCTATCTGTATTC 57
hGUS-R 20 TCCCCACAGGGAGTGTGTAG  
hNIPBL-L 19 CTATGCGAACAGCCCAAAA 55
hNIPBL-R 24 TTCACCTTGCTTACTACCACATTT  
hRAD21-L 20 ATTGACCCAGAGCCTGTGAT 62
hRAD21-R 20 GGGGAAGCTCTACAGGTGGT  
HRUNX1-L 18 ACAAACCCACCGCAAGTC 21
HRUNX1-R 23 CATCTAGTTTCTGCCGATGTCTT  
HSPI1-L 20 CTGGAGTTCCCCAATCACAT 25
HSPI1-R 23 TGATTTCAGACATGACAAAAGGA  
TA B L E  2   Human primer sequences and 
probe numbers used in qPCR experiments
PRIMER Length Sequence
zrpl8-L 21 CTCCGTCTTCAAAGACCATGT
zrpl8-R 21 TCCTTCACGATCCCCTTGATG
zP1-runx1-L 20 ATGGCCTCCAACAGCATCTT
zP2-runx1-L 20 GAGCCGAAACTCACGGAGAC
zrunx1 common-R 20 GCAAACCCTCGCTCATCTTC
zspi1b-L 19 GCCATTTCATGGACCCAGG
zspi1b-R 19 ACACCGATGTCCGGGGCAA
zgata1a-L 26 AACGACATCTTCAATACTACACTTGC
zgata1a-R 18 GGACACCCAACGAGAAGG
TA B L E  3   Zebrafish primer sequences 
used in qPCR experiments
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standard deviation (SD) values refer to data from triplicate samples. 
In zebrafish, at least three different experiments were done for each 
analysis.
The degree of linear relationship between RAD21, NIPBL, RUNX1, 
MPL and SPI1 expression levels was calculated using Spearman's cor-
relation coefficient (r value).
2.7 | TRAM analysis
TRAM (Transcriptome Mapper) software36 allows the import, de-
coding of probe set identifiers to gene symbols via UniGene data 
parsing,37 integration and normalization of gene expression data in 
tab-delimited text format for the generation and analysis of tran-
scriptome maps. We analysed the transcriptome map previously 
obtained from a gene expression profile datasets for normal human 
megakaryocytes (MK) cells derived from healthy donors.38 The data-
set is composed of 19 samples previously described (Pool D in Ref. 
38). In particular, we used the function "Export" of TRAM software 
in order to obtain normalized expression values assigned to NIPBL, 
RAD21, RUNX1 and MPL genes for each sample. The degree of linear 
relationship between RAD21, NIPBL, RUNX1, MPL and SPI1 expres-
sion levels was calculated using Spearman's correlation coefficient 
(r value).
3  | RESULTS
3.1 | Positive correlation between NIPBL and 
RUNX1 expression in normal megakaryocytes derived 
from healthy donors and bone marrow cells derived 
from adult AML patients
RUNX1 expression has been reported to be regulated by the co-
hesin subunit RAD21 and the CTCF insulator in human myelocytic 
leukaemia cells HL-60.26 As RUNX1 is pivotal in the differentiation 
of megakaryocytes and myeloid lineages, we investigated the rela-
tive expression of RAD21 and RUNX1 in two different contexts in 
F I G U R E  1   Positive correlation 
between NIPBL and RUNX1 expression 
in megakaryocytes derived from healthy 
donors and in bone marrow cells derived 
from 34 adult AML patients. A and B, 
Spearman's correlation between RUNX1 
and RAD21 (A) or NIPBL (B) in cord blood 
megakaryocytes (MK) derived from 
healthy donors. C and D, Spearman's 
correlation between RUNX1 and RAD21 
(C) or NIPBL (D) in bone marrow cells 
(BM) derived from 34 adult AML patients 
without aberrant RUNX1 alterations 
(mutations or translocations). E and F, 
Spearman's correlation between RUNX1 
and NIPBL in 34 adult AML patients 
without (NPM1wt) (E) or with NPM1 
mutation (NPMc+) (F). Spearman's 
correlation analysis showed a significant 
positive correlation of the ratio of RUNX1 
expression only versus NIPBL, not versus 
RAD21,. r = Spearman's correlation 
coefficient
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which RUNX1 exerts important functions: the differentiation of the 
megakaryocytes and myeloid compartments under physiological 
and pathological conditions. For the megakaryocytes compartment 
in physiological condition, we performed in silico analyses of quan-
titative transcriptome maps, using TRAM (Transcriptome Mapper) 
software, which allows import and effective integration of data 
obtained by different experimenters, experimental platforms and 
data sources.36 In megakaryocytes (MK) derived from healthy do-
nors, RAD21 expression did not correlate with the expression levels 
of RUNX1 (Figure 1A). Conversely, we found a positive correlation 
between the expression of RUNX1 and that of NIPBL, another mem-
ber of the cohesin complex (Figure 1B). To explore the myeloid com-
partment under pathological condition, we used bone marrow (BM) 
cells derived from adult AML patients. Similar to TRAM analyses, 
when RAD21 and RUNX1 expressions were investigated in a cohort 
of 34 AML adult patients without anomalies in chromosome 21 that 
contains the RUNX1 locus, no significant correlation was reported 
(Figure 1C). Conversely, we observed the positive NIPBL/RUNX1 cor-
relation already detected in megakaryocytes (Figure 1D).
We previously showed that NIPBL transcript abundance is de-
creased in AML patients carrying the mutated NUCLEOPHOSMIN1 
(NPM1), which transfers NPM1 in the cytoplasm (NPMc+), com-
pared to the NPM1 wild-type (NPM1wt).34 Therefore, we analysed 
the correlation between the expression of NIPBL and RUNX1 in BM 
cells derived from 20 patients NPMc+, selected among the 34 AML 
patients, compared to 14 patients NPM1wt and found a significant 
positive correlation in NPMc+ but not in NPM1wt AML patients 
(Figure 1E-F). Taken together, these findings suggest a new role for 
NIPBL, different from that of RAD21, in the regulation of RUNX1 
expression and that aberrant expression of NIPBL, such as in AML 
patients with NPM+ mutation, might lead to alteration in RUNX1 
transcript levels.
3.2 | Knock-down of nipblb specifically reduces 
runx1 expression in zebrafish
To confirm the positive correlation between NIPBL and RUNX1 
observed in human, we took advantage of a zebrafish model with 
down-regulation of nipblb, the orthologue of the human NIPBL, 
previously generated in our laboratory.34 The expression of runx1 
was analysed in embryos at 30 and 48 hpf as definitive HSCs arise 
from the vascular endothelium from these developmental stages. 
Moreover, we verified that both P1-P2runx1 isoforms were highly 
expressed from 24 hpf (Figure S1). WISH analyses showed a reduc-
tion of the runx1 transcript in the aorta-gonad mesonephric (AGM) 
tissue in nipblb-MO-injected embryos compared to controls at the 
same developmental stage. The injection of the full-length runx1/
mRNA rescued this phenotype as expected (Figure 2A-C). As the 
full-length runx1 riboprobe does not distinguish between the P1- 
and P2runx1 isoforms present in zebrafish,8 we performed RT-qPCR 
analysis of both isoforms, revealing a significant reduction exclu-
sively in P2runx1 transcript levels following nipblb down-regulation. 
The expression of both isoforms was increased in embryos injected 
with nipblb-MO and runx1mRNA, confirming the efficacy of the 
runx1 overexpression (Figure 2D-E). These results provide evidence 
that nipblb knock-down causes the reduction of runx1 in zebrafish, 
confirming the positive correlation between NIPBL and RUNX1 ex-
pression observed in normal megakaryocytes and in BM of  AML 
patients.
F I G U R E  2   runx1 expression is 
specifically reduced following nipblb 
down-regulation. A-C WISH analyses 
of runx1 expression at the stage of 
30 hpf in embryos injected with control 
morpholino (ctrl-MO) (A), nipblb-MO 
(B) and nipblb-MO with runx1-mRNA 
(C). The runx1 expression in the caudal 
region (higher magnification in the box) is 
reduced following nipblb down-regulation 
and rescued in embryos co-injected 
with nipblb-MO and runx1 mRNA. E-F, 
RT-qPCR analyses of the P1runx1 (D) 
and P2runx1 (E) isoforms in ctrl-MO-, 
nipblb-MO- and nipblb-MO/runx1mRNA-
injected embryos at 48 hpf. Scale bars 
indicate 100 μm. One-way ANOVA with 
Bonferroni correction, **P < .01, *P < .05, 
n.s: non-significant
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F I G U R E  3   NIPBL-mediated RUNX1 down-regulation leads to impaired expression of RUNX1 target genes in both human and zebrafish. 
A, Spearman's correlation between RUNX1 and MPL in cord blood megakaryocytes (MK) derived from healthy donors. B, Spearman's 
correlation between RUNX1 and SPI1 in bone marrow cells (BM) derived from 34 adult AML patients without aberrant RUNX1 alterations 
(mutations or translocations). r = Spearman's correlation coefficient. C and D, RT-qPCR analyses of 48 hpf ctrl-, nipblb- and nipblb-
MO/runx1mRNA-injected embryos. C, The expression of the erythroid marker gata1a was decreased following nipblb-MO injection in 
comparison with controls and rescued in nipblb-MO/runx1mRNA-injected embryos. D, The expression of the myeloid marker spi1b was 
increased in both nipblb-MO- and nipblb-MO/runx1mRNA-injected embryos in comparison with controls. E-G, O-dianisidine staining showed 
a reduction of mature circulating erythrocytes in nipblb-MO-injected embryos at 48 hpf in comparison with ctrl-MO. Co-injection with 
the full-length runx1 mRNA rescues the o-dianisidine reduction. Lateral views anterior to the left (upper panels) and ventral views of the 
anterior region (lower panels). H-J, WISH analyses showed an increased expression of spi1b in nipblb-MO- and nipblb-MO/runx1mRNA-
injected embryos in comparison with ctrl-MO. Scale bars indicate 100 μm in (E-G) and 200 in μm in (H-J). One-way ANOVA with Bonferroni 
correction, ***P < .001 **P < .01, *P < .05, n.s: non-significant
A B
C
E F G
H I J
D
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3.3 | NIPBL-mediated RUNX1 down-regulation 
impairs the expression of RUNX1 target genes
We further verified whether the NIPBL-mediated RUNX1 reduction 
affects the expression of RUNX1 haematopoietic downstream tar-
gets. In MK cells derived from healthy donors, we observed a positive 
correlation between the expression of RUNX1 and that of MPL gene, 
the marker of megakaryocyte/platelet differentiation (Figure 3A).39 
In BM cells derived from AML human patients, we showed a positive 
correlation between the expression of RUNX1 and its targets SPI1, 
the marker of myeloid precursors (Figure 3B).40 The expression of 
runx1 targets gata1a and spi1b was investigated also in zebrafish in 
nipblb-MO-injected embryos and controls at 48 hpf. The expression 
of gata1a, analysed by RT-qPCR, was significantly decreased follow-
ing nipblb down-regulation as a result of runx1 reduction. Indeed, 
the injection of the runx1mRNA in the nipblb-MO-injected embryos 
rescued the gata1a expression (Figure 3C). Conversely, the expres-
sion of spi1b was significantly increased in both nipblb-MO- and 
nipblb-MO/runx1mRNA-injected embryos (Figure 3D). Consistent 
with the role of runx1 in the positive regulation of the erythroid 
lineage, mature circulating erythrocytes, visualized by o-dianisidine 
staining at 48 hpf, were drastically reduced in nipblb-MO-injected 
embryos (70%; N = 140), compared to controls (Figure 3E-F). This 
phenotype is not caused by alterations in vascular tree development 
as shown in the Tg(fli1a:EGFP)y1 embryos (Figure S2), or absence of 
blood flow (data not shown). The reduction of o-dianisidine-positive 
erythrocytes was rescued in the 75% of the nipblb-MO-runx1mRNA-
injected embryos (N = 113) (Figure 3G), confirming that the pheno-
type is dependent on nipblb-mediated runx1 reduction.
WISH analyses of spi1b expression showed the increase of the 
transcript in the CHT of nipblb-MO-injected embryos (Figure 3H-I) 
confirming the RT-qPCR data and our previous findings.34 In agree-
ment with the positive regulation exerted by runx1 on spi1b, the 
injection of the runx1/mRNA further enhanced this phenotype 
(Figure 3J).40
As it has been previously demonstrated that rad21, another mem-
ber of the cohesin complex, regulates runx1 in zebrafish embryos 
during primitive haematopoiesis,25,26 we further verified the ex-
pression of runx1 during definitive haematopoiesis following rad21 
down-regulation by means of morpholino injection.25 rad21-MO-in-
jected embryos at 48 hpf showed an increased expression of both P1 
and P2runx1 isoforms and a consequent increase in the expression of 
the runx1 downstream targets gata1a and spi1b (Figure 4A-D). These 
data are in agreement with the negative regulation exerted by RAD21 
on RUNX1 expression reported in the myeloid HL60 cell line.26
4  | DISCUSSION
The transcription factor RUNX1 is a pivotal gene in the develop-
ment and differentiation of HSCs: as transcription factor, it con-
trols the expression of master genes involved in megakaryocytes 
and myeloid lineages differentiation, and it interacts with different 
proteins fundamental during haematopoiesis. Somatic transloca-
tions and mutations of RUNX1 are causative of haematological dis-
eases such as myelodysplastic syndrome, acute myeloid leukaemia, 
acute lymphoblastic leukaemia, chronic myelomonocytic leukae-
mia and acute megakaryoblastic leukaemia with familial platelet 
disorder. In addition, dysregulation of RUNX1 expression might 
lead to impaired haematopoiesis and the insurgence of a patho-
logical condition. Among the genes discovered to regulate RUNX1, 
there is RAD21, a member of the cohesin complex, and the CTCF 
insulator.26 In human K562 cells and murine and zebrafish models, 
RAD21 and CTCF bind to a cis-regulatory element (CRE) enhancer 
located in an intron between the P1 and P2RUNX1 promoters, 
associated with RNApolII.41 As cohesins preferentially bind to 
transcriptionally active genes and recruit RNAPolII and chroma-
tin modifiers to activate gene transcription,42 it would have been 
expected that RAD21 positively regulates RUNX1 transcription by 
binding to the CRE between P1 and P2 promoters. This finding is 
reported by Supernat and colleagues 43 in patients with endome-
trial cancers. However, in a zebrafish mutant for Rad21 the expres-
sion of runx1 was reduced 25 and the P1 and P2runx1 isoforms were 
differently expressed: P1 isoform was increased, while P2 was not 
varied or even decreased following Rad21 depletion.26 Moreover, 
the silencing of RAD21 in the human HL60 leukaemic cell line leads 
to an enhanced expression of RUNX1 indicating that RAD21 might 
also repress RUNX1 expression.26 In our study, we did not observe 
F I G U R E  4   The down-regulation of rad21 in zebrafish enhances 
the expression of runx1 and its downstream targets gata1a and 
spi1b. A-D, RT-qPCR analyses of 48 hpf ctrl- and rad21-MO-
injected embryos. The expression of both P1 (A) and P2runx1 (B) 
isoforms and of runx1 targets gata1a (C) and spi1b (D) was increased 
following rad21-MO injection in comparison to  controls at 48 hpf. 
One-way ANOVA with Bonferroni correction, ***P < .001, **P < .01, 
*P < .05, n.s: non-significant
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a significant correlation between the expression of RAD21 and 
RUNX1 neither in megakaryocytes derived from healthy donors, 
nor in bone marrow cells derived from a selected cohort of adult 
AML patients. However, we showed that during definitive haema-
topoiesis, the down-regulation of rad21 in zebrafish enhances the 
expression of both P1 and P2runx1 isoforms leading to impaired 
expression of the runx1 downstream targets gata1a and spi1b.
The different members of the cohesin complex can exert similar 
or individual functions in the regulation of gene expression. For ex-
ample, Zuin et al44 demonstrated that NIPBL binds to chromatin in-
dependently in time and space than other cohesins, revealing a new 
role for NIPBL as transcriptional regulator not linked to the cohesin 
complex. In this work, we demonstrate that NIPBL exerts a differ-
ent regulation on RUNX1 expression than RAD21. Indeed, in three 
different contexts: normal megakaryocytes derived from healthy 
donors, bone marrow cells derived from adult AML patients and 
zebrafish embryos with nipblb down-regulation, we demonstrate a 
positive correlation between NIPBL and RUNX1 expression.
The NIPBL-mediated RUNX1 dysregulation affects the RUNX1 
downstream targets responsible for the differentiation of the eryth-
roid and myeloid lineages. RUNX1 augmented GATA1-mediated 
promoter activation; in this regard, the decrease in RUNX1 tran-
scription/activity leads to down-regulation of the erythroid GATA1 
transcription factor.45 Interestingly, cohesins-haploinsufficient cells 
presented enriched or depleted GATA1 consensus binding sites in-
dicating that they can modulate GATA1 activity directly or through 
other molecules.12,46
Also the SPI expression is positively regulated by RUNX1, facil-
itating the interaction between the SPI enhancer and its proximal 
promoter.47 Indeed, we observed a positive correlation between 
RUNX1 and SPI1 in human samples and in zebrafish when we forced 
runx1 expression. However, following nipblb down-regulation, we 
also observed an increase in spi1b expression according to our pre-
vious data.34 This result does not correlate with the runx1 reduc-
tion and its positive activity on spi1b expression and raises three 
possibilities: first that the increased number of myeloid precursors, 
previously reported in zebrafish following nipblb-MO injection,34 
leads to an augmented number of cells expressing spi1b with a con-
sequent total increase of spi1b transcript. Second, it has been re-
ported that the chromatin structure at the spi1b/PU.1 locus could 
be differentially regulated during the different stages of haema-
topoiesis,11 suggesting the possibility that other mechanisms than 
RUNX1 might control spi1b expression. For example, we demon-
strated that the canonical Wnt pathway, modulated by nipblb, has a 
pivotal role in regulating spi1b myeloid expression during definitive 
haematopoiesis in zebrafish.34 Moreover, in vitro and in vivo studies 
demonstrated that forced expression of gata1 down-regulates spi1b, 
while forced expression of spi1b down-regulates gata1.48–50 In this 
scenario, the nipblb-mediated runx1 down-regulation might lead to 
spi1b enforced expression that, in turn, reduces gata1a expression. 
Alternatively, the two P1 and P2runx1 isoforms might exert differ-
ent functions on spi1b regulation. Indeed, as for the case of Rad21 
zebrafish mutants,26 we demonstrated that the down-regulation of 
nipblb differently affects the two isoforms by significantly reducing 
only the P2runx1. Third, it has been demonstrated that NIPBL might 
regulate SPI1 by itself, encompassing the Runx1 regulation.44
Although in this work we did not address the mechanism through 
which NIPBL regulates RUNX1 expression, we demonstrated that 
NIPBL positively regulates RUNX1 transcription and that the link 
between NIPBL dysregulation and RUNX1-driven haematopoietic 
defects might  explain haematological malignancy occurrence. Thus, 
also in the absence of RUNX1 translocation or mutations, additional 
factors such as defects in the expression of NIPBL observed in AML 
patients might contribute to haematological diseases.
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